Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E48.02 EPS (ttm)7.71 Insider Own1.40% Shs Outstand106.61M Perf Week-1.67%
Market Cap39.47B Forward P/E23.59 EPS next Y15.70 Insider Trans-0.48% Shs Float78.08M Perf Month4.48%
Income895.50M PEG2.57 EPS next Q3.08 Inst Own69.60% Short Float2.59% Perf Quarter-6.86%
Sales4.86B P/S8.12 EPS this Y39.50% Inst Trans-2.11% Short Ratio2.16 Perf Half Y-11.57%
Book/sh42.33 P/B8.75 EPS next Y20.56% ROA13.80% Target Price422.68 Perf Year-4.29%
Cash/sh9.74 P/C38.00 EPS next 5Y18.68% ROE21.30% 52W Range325.35 - 452.96 Perf YTD0.85%
Dividend- P/FCF41.05 EPS past 5Y38.80% ROI18.20% 52W High-20.69% Beta1.38
Dividend %- Quick Ratio2.30 Sales past 5Y61.30% Gross Margin93.80% 52W Low10.42% ATR9.25
Employees5400 Current Ratio2.60 Sales Q/Q11.70% Oper. Margin27.40% RSI (14)45.64 Volatility2.10% 2.67%
OptionableYes Debt/Eq0.11 EPS Q/Q63.00% Profit Margin18.40% Rel Volume1.44 Prev Close370.22
ShortableYes LT Debt/Eq0.08 EarningsFeb 09 BMO Payout0.00% Avg Volume934.80K Price359.24
Recom2.20 SMA20-0.73% SMA50-2.21% SMA200-6.23% Volume316,261 Change-2.97%
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Feb-16-17 09:20AM  Why Amgen's Becoming One of My Top Dividend Stocks to Buy at Motley Fool
08:17AM  Regeneron Pharma downgraded by Goldman
Feb-15-17 01:04PM  REGENERON PHARMACEUTICALS INC Financials
07:04AM  Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
Feb-14-17 05:12PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : February 14, 2017
08:33AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : February 14, 2017
07:54AM  These 25 Companies Could Get a Big Profit Boost From a Little Known Part of Trump's Tax Reform
Feb-13-17 02:25PM  Regeneron: It's All Riding On Dupixent at Barrons.com
10:49AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017
09:30AM  Regeneron Announces Upcoming 2017 Investor Conference Presentations PR Newswire
07:45AM  Early movers: AAPL, DD, TEVA, QSR, FDC, HAS, JCP & more at CNBC
Feb-10-17 02:50PM  3 Beaten-Down Stocks Ready to Bounce Back at Motley Fool
09:17AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017
08:15AM  Blog Coverage Acorda's Stock Price Soared Above 20% on Positive Data from Parkinson Disease Late Stage Clinical Trial Accesswire
05:54AM  [$$] 12 Stocks to Benefit Most From the House Tax Plan at Barrons.com
Feb-09-17 06:00PM  Edited Transcript of REGN earnings conference call or presentation 9-Feb-17 1:30pm GMT
04:56PM  Regeneron Defies Light Q4 Sales, Eylea Outlook On Amgen-Rivaling LDL Win
04:26PM  Regeneron says it is being investigated by the US Attorney's Office over patient assistance nonprofit at MarketWatch
02:01PM  Regeneron: Whiplash! at Barrons.com
01:14PM  [$$] Regeneron Is Primed for a Second Act at The Wall Street Journal
01:11PM  Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales at Insider Monkey
11:09AM  Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
10:56AM  Judge Lifts Ban on Amgen Cholesterol Drug Rival at Investopedia
10:03AM  Regeneron (REGN) Q4 Earnings Misses Estimates
09:05AM  Acorda, Amgen and Regeneron Lead Premarket Biotech Movers
08:33AM  Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
08:31AM  Regeneron forecasts 2017 U.S. Eylea sales growth below estimates
08:17AM  A Heart-Stopping Patent Injunction Stay For Sanofi at Forbes
07:51AM  Early movers: KO, TWTR, VIAB, CVS, YUM, RAI, & more at CNBC
07:17AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:17AM  Regeneron misses Street 4Q forecasts
07:07AM  Q4 2016 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open
06:37AM  Regeneron revenue rises 11.7 pct on Eylea eye drug
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2016 Financial and Operating Results PR Newswire
Feb-08-17 07:02PM  [$$] Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug at The Wall Street Journal
05:46PM  Sanofi: Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process GlobeNewswire
05:33PM  Regeneron, Sanofi Temporarily Stave Off Ban Of Amgen-Rivaling LDL-Buster
05:30PM  Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process PR Newswire
04:49PM  Federal appeals court decision will keep Regeneron/Sanofi drug at center of patent dispute on market, for now at MarketWatch
04:39PM  Judge: Regeneron can keep selling cholesterol drug
04:14PM  Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
08:08AM  [$$] Sanofi Seeks Cure for FDA Concerns at French Factory at The Wall Street Journal
07:27AM  Earnings Preview: What To Expect From Regeneron On Thursday at Forbes
03:25AM  Drugmaker Sanofi sees weak 2017 earnings, not in hurry for M&A
Feb-07-17 06:30AM  Regeneron to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2017 PR Newswire
06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
05:43AM  [$$] Where a Go-Anywhere Fund Is Finding Growth at Barrons.com
Feb-03-17 04:24PM  Amgen's LDL-Buster Boosts The Medicines Co., But Regeneron Slides
Feb-02-17 04:58PM  Amgen Crushes Q4 Views, But Sees Light 2017 Sales; Repatha Tops CV Study
04:27PM  Amgen Cholesterol-Lowering Drug Repatha Cuts Heart-Related Adverse Events in Big Study
Feb-01-17 07:50AM  SanofiRegeneron Sarilumab Approved in Canada for Arthritis
01:03AM  Sanofi and Regeneron Announce First Approval of Kevzara(TM) (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada GlobeNewswire
01:00AM  Regeneron and Sanofi Announce First Approval of Kevzara (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada PR Newswire
Jan-31-17 08:35AM  Merrill Lynch Says 5 Companies Could Benefit Huge From Trump Tax Plan 24/7 Wall St.
07:00AM  Tony Coles, M.D., Elected to Regeneron Board of Directors PR Newswire
Jan-30-17 04:18PM  Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug
11:30AM  11 Highest Paid CEOs In The World at Insider Monkey
Jan-26-17 01:21PM  Biotech ETFs: Is It Time To Buy? at Barrons.com
12:27PM  Manning & Napier's Top 3 New Holdings
07:01AM  3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000 at Motley Fool
Jan-24-17 03:35PM  Is Amgens Cardiovascular Segment Still a Growth Opportunity?
12:00PM  Forty of Nation's Brightest Young Scientists Named Regeneron Science Talent Search 2017 Finalists PR Newswire
08:04AM  On Experiencing The Failure Of A Billion-Dollar Clinical Program at Forbes
Jan-23-17 02:16PM  Top Biotech Stocks to Buy in 2017 at Motley Fool
12:00PM  Failed Mergers Cast Shadow on Sanofi's Future at Investopedia
Jan-20-17 08:19AM  Regeneron Pharmaceuticals Could Be Ready to Rebound
06:29AM  Here are the stock markets biggest winners and losers during Obamas presidency at MarketWatch
Jan-19-17 12:55PM  These Insiders Are Still Finding Some Good Value in the Stock Market
11:11AM  A Green Light on Bayer
Jan-18-17 09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
Jan-17-17 04:43PM  Regeneron, Sanofi Claim Amgen's LDL-Buster Patent Too Broad
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-15-17 07:10AM  Why Regeneron Pharmaceuticals, Inc. Stock Slipped 32.4% in 2016 at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
Jan-12-17 12:04PM  Regeneron, Sanofi's Drug Manufacturing Plant Cleared at Investopedia
11:56AM  [$$] Sanofi confident it can overturn Praluent patent ruling at Financial Times
10:05AM  Merrill Lynch Has 4 Red-Hot Stocks to Buy With Up to 75% Upside Potential
Jan-11-17 01:26PM  Trump's Comments Are Big Pharma's Nightmare at Forbes
12:26PM  Trump's Comments Are Big Pharma's Nightmare
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes +5.05%
11:26AM  Regeneron CEO: The industry doesn't put patients first
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals
08:53AM  2 Top Stocks in Biotech at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 08:48PM  Regeneron CEO says Amgen not putting patients first in patent dispute Reuters
05:23PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at Barrons.com
10:10AM  Company News for January 09, 2017
09:00AM  The FDA Approved Fewer Drugs in 2016: Here's Why
08:15AM  Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US Accesswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 11:13AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Pfizer at Motley Fool
10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 08:09PM  Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17) -5.84%
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
06:35PM  The Biggest Loser: Regeneron Sinks 5.8% at Barrons.com
04:56PM  [$$] Amgen Patent Win Boosts Odds of a Stock Comeback at Barrons.com
04:42PM  Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM